- $516.99m
- $175.48m
- $2.85m
Annual balance sheet for Upstream Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Cash and Equivalents | ||||
| Short Term Investments | ||||
| Cash and Short Term Investments | 17.1 | 110 | 470 | 342 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.412 | 0.236 | 1.18 | 2.32 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | 18.3 | 117 | 479 | 352 |
| Gross Property, Plant And Equipment | ||||
| Accumulated Depreciation | ||||
| Net Property, Plant And Equipment | 0.164 | 0.202 | 2.37 | 1.78 |
| Other Long Term Assets | ||||
| Total Assets | 18.5 | 117 | 482 | 354 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 4.86 | 6.51 | 10.7 | 13.5 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | 11.8 | 9.39 | 11.9 | 14 |
| Redeemable Preferred Stock | ||||
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Unrealized Gain / Loss | ||||
| Total Equity | 6.67 | 108 | 470 | 340 |
| Total Liabilities & Shareholders' Equity | 18.5 | 117 | 482 | 354 |
| Total Common Shares Outstanding |